echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Allogene's multiple myeloma therapy ALLO-715 won the FDA rare disease drug title

    Allogene's multiple myeloma therapy ALLO-715 won the FDA rare disease drug title

    • Last Update: 2021-08-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompilationTom Lee

    A few days ago, the U.


    ALLO-715 is a CAR-T therapy targeting B cell maturation antigen (BCMA) and a potential new therapy for the treatment of multiple myeloma and other BCMA-positive malignancies


    Phase 1 data from the UNIVERSAL trial proves that allogeneic CAR-T therapy for BCMA can achieve clinical response while eliminating the need for bridging therapy or manufacturing-related treatment delays


    The test results also showed that CAR-T therapy ALLO-715 showed good tolerance in relapsed/refractory multiple myeloma.


    Multiple myeloma is the second most common hematological malignancy after non-Hodgkin's lymphoma


    In April 2021, ALLO-715 was again awarded the FDA Regenerative Medicine Advanced Therapy (RMAT) designation


    Although the market space of CAR-T has great potential, the competition is also very fierce


    Reference source:

    1.


    2.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.